New LabPAS/CT V 2.5, Complete P1 Trial Workflow System with PDA, to be Unveiled at DIA Annual Meeting
Green Mountain Logic will unveil LabPAS/CT Version 2.5 at the DIA Annual Meeting.
Philadelphia, June 18–21, booth # 1520-Version 2.5 deploys PDAs on clinic floors to scan patient and collection vessel barcodes, eliminating the potential for errors. It provides real time electronic data entry for collection times, comments, dosing, vital signs and adverse events. LabPAS/CT 2.5 also allows integration with document management systems and with biometric systems for positive subject ID.
LabPAS/CT uses a Web interface and intuitive navigation and is the most scalable, configurable and customizable workflow and sample management solution on the market today. Through the innovative use of barcode scanning it eliminates errors, tracks samples, increases throughput, and supports compliance. In addition, sample collection and dosing are scheduled and tracked according to trial protocols. LabPAS/CT supports compliance with FDA 21 CFR Part 11, GCP and GLP, and also empowers study managers to rapidly alter workflow and schedules as protocols change, by simply dragging and dropping items on their computer screen. It was developed under Green Mountain Logic's design control process, audited and approved by multiple, nationally-recognized pharmaceutical clients. GML is in compliance with FDA guidance for the development of high-risk software systems and for development of Class 2 Medical Devices.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
